Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration

Stopped early · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Fuchs' Endothelial Dystrophy

In brief

Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central endothelial cell layer.

Key facts

Study ID

NCT03971357

Run by

Price Vision Group

People needed

19

Starts

2019-07-22

Expected to finish

2021-08-26

Last updated by the study team

2023-02-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patient at least 18 years of age and of any race or ethnicity who is undergoing Descemet stripping only for Fuchs dystrophy
• Is able and willing to administer eye drops
• Is able to comprehend and has signed the Informed Consent form.

You may not qualify if…

• Active intraocular inflammation
• Corneal ulceration, keratitis, or conjunctivitis
• Known sensitivity to any of the ingredients in the study medications
• Abnormal eyelid function
• History of herpetic keratitis
• History of non-compliance with using prescribed medication
• Current or planned pregnancy within the study duration
• Concurrent involvement or participation in another randomized clinical trial within 30 days prior to enrollment in this study
• Any ocular or systemic condition (i.e., UNCONTROLLED systemic disease) or situation which in the investigator's opinion may put the patient at significant risk, confound the study results, or interfere significantly with the patient's participation in the study.

Where it is running

• Price Vision Group — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.